LGALS3 and pulmonary fibrosis: In addition, recent clinical trials show that suppressing Gal-3 expression with TD139 decreases the plasma levels of biomarkers associated with idiopathic pulmonary fibrosis progression [134, 135], suggesting Gal-3 as a promising therapeutic target.